Center-Authored Papers

Filters: Author is Heijnsdijk, Eveline A M  [Clear All Filters]
Journal Article
Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EAM, Katcher J, de Koning HJ, Etzioni R.  2012.  The impact of PLCO control arm contamination on perceived PSA screening efficacy.. Cancer causes & control : CCC. 23(6):827-35. Abstract
Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R.  2017.  Is prostate cancer different in black men? Answers from 3 natural history models. Cancer. Abstract
Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EAM, Pabiniak C, van Ballegooijen M et al..  2014.  Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.. Annals of internal medicine. 161(2):104-12. Abstract
Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EAM, Katcher J, Draisma G, Feuer EJ, de Koning HJ et al..  2012.  The prostate cancer conundrum revisited : Treatment changes and prostate cancer mortality declines.. Cancer. Abstract
Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A et al..  2017.  Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.. Annals of internal medicine. Abstract
Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LYT, Katcher J, Lee S-Y, Heijnsdijk EAM, Draisma G, de Koning HJ et al..  2011.  What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(5):740-50. Abstract